Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.
Status:
Terminated
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the effects and safety of Ruxolitinib, a Janus kinase
1 (JAK1) and Janus kinase 2 (JAK2) inhibitor for the treatment of tumor-associated cachexia
in chronic wasting diseases.
Phase:
Phase 2
Details
Lead Sponsor:
Kantonsspital Aarau
Collaborators:
Clinical Trial Unit, University Hospital Basel, Switzerland Novartis University Hospital, Basel, Switzerland